Crescent Biopharma, Inc.

NASDAQ:CBIO

Biotechnology

Healthcare
$12.40 -2.69%

-$0.49 today

Market cap
$482.30M
Beta
1.15
P/E (TTM)
-3.3
EPS (TTM)
-$5.33
52W Low $8.72High $27.41

Volume 0.33M

Average 0.28M

CBIO Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Crescent Biopharma, Inc.NASDAQ: CBIO

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 30.4M shares rose 55.9% year over year, ahead of the -57.8% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 50.7% from the prior quarter. Over 3 fiscal years it compounded at -41.7% a year.

Context

  • Weighted avg shares (diluted) increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +55.9% holds above the trailing-twelve-month pace of -57.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
30.4M+50.7% QoQ
Last fiscal yearDec 2025
10.41M-46.6% YoY
LTMMar 2026
17.74M-57.8% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+55.9%——
1 year-46.6%——
3-year CAGR-41.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
10.41M USD
Year-over-year change
-46.6%
4-year CAGR
-32.9%

Weighted Avg Shares (Diluted) vs competitors

How CBIO compares with its peers on the latest reported figures

  • CBIO's LTM Mar 2026 weighted avg shares (diluted) of 17.74M shares is the lowest of the 10 companies compared; the peer median is 94.08M shares.
  • Its year-over-year change of -57.8% is the lowest of 10, against a peer median of +9.0%.
  • Over three fiscal years its annual growth of -41.7% compares with a peer median of +12.4%.
CBIO Competitors Peer median
Weighted Avg Shares (Diluted) for CBIO and competitors
Company Period LTM YoY 3-year CAGR
CMPXCompass Therapeutics, Inc.LTM Mar 2026161.95M +17.8%+14.5%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026160.38M +90.2%+28.0%
RCUSArcus Biosciences, Inc.LTM Jun 2026116.35M +19.9%+14.3%
CNTXContext Therapeutics Inc.LTM Mar 202694.36M +30.6%+81.3%
CGENCompugen Ltd.LTM Mar 202694.08M +4.2%+2.7%
ZYMEZymeworks Inc.LTM Sep 202674.82M -1.6%+4.9%
CLDXCelldex Therapeutics, Inc.LTM Sep 202672.36M +9.0%+12.4%
NBPNovaBridge BiosciencesLTM Sep 202572.17M -11.6%-20.4%
MGNXMacroGenics, Inc.LTM Mar 202663.26M +0.8%+0.9%
CBIOCrescent Biopharma, Inc.LTM Mar 202617.74M -57.8%-41.7%
VRXAVeraxa Biotech Holding AG—— ——
Peer median (excluding CBIO) 94.08M+9.0%+12.4%

Competitors are the stored peer set for CBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.16M75K10K010.84M
Cost of Revenue00000
Gross Profit1.16M75K10K010.84M
Gross Margin100.0%100.0%100.0%—100.0%
Research & Development47.49M28.39M20.07M28.06M138.09M
Selling, General & Admin17.12M19.09M19.21M16.32M25.39M
Operating Expenses64.61M47.48M39.29M49.9M163.48M
Depreciation & Amortization264.6K207.15K153.3K35.17K84K
EBITDA(63.18M)(47.2M)(39.12M)(44.17M)(149.67M)
EBITDA Margin-5447.9%-62927.6%-391213.5%—-1380.2%
Operating Income(63.45M)(47.4M)(39.28M)(49.9M)(152.63M)
Operating Margin-5470.7%-63204.4%-392752.9%—-1407.5%
Interest Income19.77K714.52K2.38M1M2.88M
Interest Expense000852K2.19M
Other Income / Expenses19.77K714.96K2.38M1.37M690K
Income Before Tax(63.43M)(46.69M)(36.9M)(48.52M)(151.94M)
Pre-Tax Margin-5469.0%-62251.1%-368987.8%—-1401.2%
Income Tax Expense00002M
Net Income(63.43M)(46.69M)(36.9M)(48.52M)(153.94M)
Net Margin-5469.0%-62251.7%-368994.2%—-1419.6%
EPS (Basic)(1.23)(0.89)(0.58)(1.40)(14.78)
EPS (Diluted)(1.23)(0.89)(0.58)(1.40)(14.78)
Weighted Avg Shares51.45M52.53M63.34M19.5M10.41M
Weighted Avg Shares (Diluted)51.45M52.53M63.34M19.5M10.41M

Crescent Biopharma, Inc.

NASDAQ:CBIO

Intrinsic Alpha fair value

Locked

Current Price

$12.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.